Genentech Sends Raptiva “Dear Doctor” Letter To Dermatologists, Nurses
This article was originally published in The Pink Sheet Daily
Executive Summary
Letter addresses new warning in efalizumab labeling on immune-mediated hemolytic anemia. Two cases of hemolytic anemia were observed in clinical trials and two additional cases were observed in postmarketing adverse event monitoring.
You may also be interested in...
PML Reported In Raptiva User; Genentech Sends “Dear Doctor” Letter
Finding follows reports of PML in Rituxan, Tysabri patients earlier this year.
PML Reported In Raptiva User; Genentech Sends “Dear Doctor” Letter
Finding follows reports of PML in Rituxan, Tysabri patients earlier this year.
Genentech Will Alert Physicians To Raptiva Anemia Warning
"Dear Healthcare Provider" letter will address a hemolytic anemia warning stemming from postmarketing surveillance of the plaque psoriasis therapy. A precaution on severe arthritis events also has been added.